"These results have triggered significant interest in our stent.  We have been very pleased with the early acceptance of our new SUPERA VERITAS delivery system since introducing it to a European audience at LINC 2010," Owens added.  "We recorded a year-over-year revenue growth rate of nearly 70 percent in the first quarter of this year, and we anticipate an increasing rate of adoption and sizeable increases in market share as the launch of our new delivery system gains even greater traction in the market."    

The Company expects to introduce two additional products in its family of SUPERA stents by the end of this year.

Professor Thomas Zeller, M.D., of the Department of Vascular Medicine, Heart Center in Bad Krozingen, Germany, noted that the SUPERA VERITAS delivery system was designed to complement the flexible SUPERA stent in the treatment of obstructive arterial disease in the superficial femoral artery of the lower extremity.

"The introduction of the SUPERA VERITAS system substantially improves the delivery of the innovative and unique SUPERA stent," Dr. Zeller said.  "SUPERA may be the most durable and flexible stent currently on the market for use in treating PAD, and I believe this stent system will prove to be an important advancement in the treatment of the disease."

The SUPERA Interwoven Self-Expanding Nitinol Stent Transhepatic Biliary system has received 510(k) clearance for palliative treatment for biliary strictures produced by malignant neoplasms.   The SUPERA Interwoven Self-Expanding Nitinol Stent System has received CE Mark approval in Europe for biliary and peripheral vascular indications. The SUPERA stent is currently the focus of a prospective, FDA-approved, single-arm clinical trial of 258 patients at up to 40 sites in the U.S.

Source IDEV Technologies, Incorporated